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Abstract
Fusogenic liposome, a unique vector prepared by fusing ultraviolet-inactivated Sendai virus and liposome, is known to
efficiently deliver content into various animal cells through membrane fusion. In this study, we examined the target-cell
specificity of fusogenic liposome (FL)-mediated macromolecule delivery into human blood cells using diphtheria toxin
fragment A (DTA) as a probe. Among the peripheral blood mononuclear cells (PBMC), FL was able to deliver its
encapsulates into CD14 monocytes and CD43/CD83 T-cells, but not into CD19 B-lymphocytes, CD4 T-cells or CD8
T-cells. The susceptibility of human leukemia cell lines to FL was similar to that of PBMC; the order of the reactivity was
U937 (monoblastic leukemia)sMOLT4, Jurkat (T-lymphoma)sDaudi, BALL1 (B-lymphoma)sK562 (erythroblastic
leukemia). Interestingly, FL showed similar binding activity to all of these leukemia cell lines. These findings indicate that,
among blood cells, monocytes, monoblastic leukemia cells, CD43/CD83 T-cells and T-lymphoma cells are preferable targets
for FL-mediated macromolecule delivery. This is the first demonstration of the existence of non-permissive cells against FL.
Our results also suggest that some molecules on target-cells other than the binding targets of SV-derived protein may
participate in fusion between FL and cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
E⁄cient delivery of biological materials into living
cells is important in biological research. It is also of
primary importance in vector development for gene
therapy. Various methods and carriers have been de-
veloped, e.g. microinjection, electroporation, lipo-
somes, DEAE-dextran, and viral vectors, although
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each of these has both advantages and disadvan-
tages. Liposome introduction is the simplest among
these methods, and for this reason, liposomes have
been used as carriers for drugs and macromolecules
[1], and for DNA transfection of cells in vitro [2] and
in vivo in gene therapy [3,4]. However, using lipo-
somes, biological materials are introduced into cells
via endocytosis, and they are often digested within
endosomes by lysosomal enzymes, which results in
complete disappearance of their biological activity
[5].
Nakanishi and his colleagues developed the fuso-
genic liposome (FL) as a macromolecule delivery sys-
tem [6,7]. The FL is prepared by fusing a liposome
with a Sendai virus particle. The liposome is modi-
¢ed by the envelope proteins of Sendai virus. This
liposome can deliver its content into the cytoplasm
directly and e⁄ciently because it can fuse with cell
membrane with the aid of Sendai virus envelope gly-
coproteins. To date, liposomes modi¢ed by Sendai
virus-derived proteins have been used to successfully
introduce biologically active materials, e.g. proteins,
plasmid DNA, oligonucleotides, and ribozymes, into
animal cells [8^11]. In murine ¢broblast L-cells, it
has been clearly demonstrated that FL can transfer
DNA with higher e⁄ciency and less cytotoxicity than
lipofectin, a typical liposome reagent used for DNA
delivery [12]. The high e⁄ciency of this system is
attributable to the fact that materials introduced by
membrane fusion can escape lysosomal degradation
and reach the cytoplasm in an intact form [13]. At
present, FL is expected to become a highly useful
tool for use in gene therapy.
When using FL as a carrier, knowledge of FL
target-cell speci¢city is highly important. Based on
our previous study, FL has a wide range of target
cells. However, little is known about its reactivity
with blood cells (Mizuguchi and Nakanishi, manu-
script in preparation). Since these cells are an impor-
tant target of gene therapy and molecular biology,
we here examined the target-cell speci¢city of FL-
mediated macromolecule delivery into blood cells.
In order to examine FL-mediated macromolecule
transfer in a manner that precisely re£ected the spe-
ci¢city of membrane fusion, diphtheria toxin frag-
ment A (DTA) was used as an encapsulated mole-
cule. DTA is a useful probe for detecting membrane-
fusion mediated macromolecule delivery, because one
molecule of DTA can kill a target cell, and DTA-
containing FL (DTA-FL) has been shown to provide
data on direct fusion between FL and cytoplasmic
membranes [5,14,15]. In this report, our ¢ndings
demonstrate that susceptibility of blood cells to FL
di¡ers among cell types and that binding of FL with
cells through Sendai virus-derived protein is not
enough to guarantee membrane fusion.
2. Materials and methods
2.1. Preparation of FL
Unilamellar liposomes were prepared by the re-
verse-phase evaporation method with some modi¢-
cations [16]. Brie£y, 46 Wmol of lipids (egg phospha-
tidylcholine/L-K-dimyristoyl phosphatidic acid/
cholesterol, 5:1:4, molar ratio) in 1 ml of a mixture
of dichloromethane and diethyl ether (53:47 (w/w))
were added to 300 Wl of an aqueous solution contain-
ing 100 Wg of diphtheria toxin fragment A (DTA) or
1 mM calcein in BSS(3) (150 mM NaCl/10 mM Tris
HCl, pH 7.6). After sizing by extrusion through a
0.4-Wm polycarbonate membrane (Nucleopore, Co-
star, Cambridge, MA), liposomes were separated
from unencapsulated molecules by centrifugation.
Sendai virus, grown in 10-day-old embryonated
chicken eggs at 35.5‡C, was puri¢ed by di¡erential
centrifugation and inactivated by ultraviolet (2000 J/
cm2) irradiation. The liposomes were then mixed
with inactivated Sendai virus and incubated for 2 h
at 37‡C with shaking. FL were separated from free
liposomes and free Sendai virus by stepwise sucrose
gradient centrifugation (15^10%). FL was quanti¢ed
by an optical density (OD) of 540 nm.
2.2. Preparation of diphtheria toxin fragment A
Diphtheria toxin fragment A (DTA) was prepared
according to the method of Uchida [15] with some
modi¢cations. Brie£y, DTA was produced by
C7hm7210, a mutant bacteria strain of Corynebacte-
rium diphtheriae C7(L), and then puri¢ed by ammo-
nium sulfate fractionation and column chromatogra-
phy. Activity of DTA was con¢rmed by the ADP-
ribosylation of elongation factor-2 as described pre-
viously [17].
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2.3. Cell culture
HeLa (JCRB9004) cells were obtained from the
Japan Cancer Research Resources Bank (JCRB)
and maintained in MEM supplemented with 10%
fetal calf serum (FCS). K562 (JCRB0019), Daudi
(JCRB9071), BALL-1 (JCRB0071), MOLT4
(JCRB9031) and U937 (JCRB9021) cells obtained
from the JCRB and Jurkat (RCB0806) cells from
the RIKEN Cell Bank were maintained in RPMI
1640 medium supplemented with 10% FCS. Cells
were cultured in a humidi¢ed atmosphere of 5%
CO2/95% air at 37‡C. Before each experiment,
cells were washed and resuspended in serum-free me-
dium.
2.4. Preparation and separation of human peripheral
blood mononuclear cells (PBMC)
Peripheral blood was drawn from healthy volun-
teers using heparin as an anti-coagulant. The blood
was diluted by an equal volume of bu¡er (0.01%
glucose, 5 WM CaCl2, 98 WM MgCl2, 540 WM KCl,
14.5 mM Tris, and 126 mM NaCl) and layered on
Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden).
After centrifugation for 40 min at 400Ug, cells in the
interface of plasma and Ficoll-Paque were collected
as PBMC, washed twice with RPMI medium and
subjected to experiments.
Separation of PBMC was performed using a mag-
netic cell sorting (MACS) system (Miltenyi Biotec,
Bergisch Gladbach, Germany) [18]. To obtain mono-
cytes, PBMC were labeled by incubating with CD14
MicroBeads (anti human CD14 antibody-conjugated
microbeads, 20 Wl for 1U107 cells ; Daiichikagaku,
Tokyo, Japan) for 15 min at 4‡C in PBS(3) contain-
ing 2 mM EDTA and 0.5% BSA. Labeled cells were
applied and bound to a steel wool column in a high
magnetic ¢eld. After washing with PBS(3) contain-
ing 2 mM EDTA and 0.5% BSA, the column was
removed from the magnetic ¢eld and CD14 cells
were eluted. B-cells were obtained using CD19 Mi-
croBeads in the same manner as monocytes. After
removal of CD14 cells and CD19 cells by means
of the MACS system, T-cells were collected by the
panning method [19] as follows. The cells were
poured into a cell culture plate coated with anti-hu-
man IgG antibody (Rockland, Gilbertsville, PA) and
incubated for 30 min at 37‡C. Non-adherent cells
were then collected as puri¢ed T-cells and washed.
Further separation of T-cells into CD4, CD8, and
CD43/CD83 cells was performed using the MACS
system. CD4 T-cells were labeled with CD4 Mi-
croBeads and separated by binding to a magnetic
column. CD8 T-cells were also labeled with CD8
MicroBeads. After separation of CD4 T-cells and
CD8 T-cells, the remaining cells were once labeled
with a mixture of CD4 and CD8 MicroBeads, and
then CD43/CD83 T-cells were obtained as a passed
through fraction from the magnetic column.
The population of the separated cells was con-
¢rmed by £ow cytometry with a Cyto ACE-150
Auto Cell Screener (JASCO, Tokyo, Japan). Brie£y,
5U105 cells were labeled with 20 Wl of dye-conju-
gated antibodies for 30 min at room temperature.
After washing with PBS(3) containing 0.2% BSA
and 0.1% NaN3, cells were subjected to £ow cytom-
etry. The dye-conjugated antibodies used were as
follows: £uorescein-labeled anti-CD14 antibody
(Leinco Technologies, Ballwin, MO) for monocytes,
FITC-labeled anti-CD3 (Immunotech, Marseille,
France) for T-cells, phycoerythrin-labeled anti-
CD19 (Immunotech) for B-cells, FITC-labeled anti-
CD4 (Immunotech) for CD4 T-cells and phyco-
erythrin-labeled anti-CD8 (Immunotech) for CD8
T-cells.
2.5. FL-mediated DTA transfer into PBMC
Cells (1U105) were seeded in 96-well plates and
incubated with various concentrations of DTA-FL
in 100 Wl of RPMI(3) media for 30 min at 37‡C.
Then, 100 Wl of RPMI containing 20% FCS, which
was not heat-inactivated, was added to each well,
and cells were cultured for 24 h. Cell viability was
evaluated by Alamar blue assay [20]. Brie£y, 20 Wl of
Alamar blue dye (Iwaki Glass, Chiba, Japan) was
added to each well, and the cells were further cul-
tured for 12 h. The optical density (OD) of each well
was then measured with a microplate reader (Bio-
Tek Instruments, Winooski, VT), at test and refer-
ence wave length of 570 and 595 nm, respectively.
Viability was calculated as [(OD5703OD595 for
DTA-FL treated cells)/(OD5703OD595 for untreated
cells)U100] and expressed as a percentage of each
untreated cell. When evaluating the viability of
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CD43/CD83 T-cells, the change in OD of Alamar
blue dye by an equal number of platelets in the frac-
tion was also measured as a control and subtracted.
Because CD43/CD83 T-cells were obtained as a
fraction which passed through the magnetic column,
platelets were co-eluated with the cells.
2.6. Binding assay
Cultured human leukemia cells were washed twice
with BSS(+) (150 mM NaCl, 2 mM CaCl2, and
10 mM Tris HCl; pH 7.6). 2.5U105 cells were incu-
bated with calcein-containing FL (OD540 = 0.1) in
250 Wl of BSS(+) for 30 min at 37‡C in a microtube.
Cells were washed twice with PBS(3) and resus-
pended in PBS(3). Fluorescence intensity of the cells
was measured by £ow cytometry. The binding of
calcein-containing liposomes not containing Sendai
virus-derived proteins (calcein-L) was also measured
to detect non-speci¢c binding.
3. Results
3.1. Fusion between DTA-containing FL and PBMC
To con¢rm whether membrane fusion-mediated
macromolecule delivery can be detected using DTA
as a probe in our system, reactivity of three kinds of
liposomes, DTA-FL, DTA-liposome (DTA-L; does
not contain Sendai virus-derived proteins), and ve-
hicle-FL, was examined using HeLa cells. HeLa cells
were chosen as a representative of human cell lines.
Each kind of liposome was added to HeLa cells and
incubated for 30 min at 37‡C then cultured for 24 h.
Viability of the cells was then examined by measur-
ing the change of OD due to the reduction of Alamar
blue dye (Fig. 1A) [20]. DTA-FL decreased the via-
bility of HeLa cells in a dose-dependent manner. In
contrast, neither DTA-L nor vehicle-FL showed any
e¡ect, indicating that the decrease in viability is spe-
ci¢c to membrane fusion-mediated delivery of DTA
by FL. Having veri¢ed the assay method, we next
examined the e¡ects of DTA-FL on PBMC. Interest-
ingly, the viability of PBMC treated with DTA-FL
was maintained at about 60% that of untreated cells,
even at a DTA-FL dosage su⁄cient to kill HeLa
cells (Fig. 1B). These results suggest that PBMC con-
Fig. 1. E¡ect of DTA-FL on HeLa cells and PBMC. (A) HeLa cells were seeded in 96-well plates and incubated with various concen-
trations of DTA-FL (closed circle), DTA-liposome (open triangle), or vehicle-FL (open square) for 30 min at 37‡C. After culturing
for 24 h, Alamar blue dye was added to each well and the OD5703OD595 of the wells was measured. Viability was calculated as
[(OD5703OD595 for DTA-FL treated cells)/(OD5703OD595 for untreated cells)U100] and expressed as a percentage of each untreated
cell. (B) PBMC were prepared as described in Section 2 and incubated with DTA-FL for 30 min at 37‡C, and then cell viability was
measured by Alamar blue assay.
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tain subpopulations which di¡er in their susceptibil-
ity to FL.
3.2. Fusion between FL and subpopulations of PBMC
Since human blood mononuclear cells are impor-
tant targets not only for biochemical research, but
also for therapy, we further examined the reactivity
of FL with the respective cell populations of PBMC.
PBMC were separated into subpopulations by anti-
body-conjugated magnetic beads as described in Sec-
tion 2. After separating PBMC into monocytes, B-
cells, and T-cells, each type of cell was incubated
with DTA-FL (OD = 0.3) or vehicle-FL. This dose
of DTA-FL was su⁄cient to kill HeLa cells, as
shown in Fig. 1. DTA-FL caused a marked decrease
in the viability of CD14 monocytes, but did not
a¡ect CD19 B-lymphocytes at all (Fig. 2A). On
Fig. 2. Cell type speci¢c fusion of FL among PBMC. Human PBMC were separated into monocytes, B-cells and T-cells as described
in Section 2. Susceptibility to DTA-FL was examined (A) and the expression of cell surface markers was con¢rmed by £ow cytometry
(B). (A) Susceptibility to FL. Cells were incubated with FL containing DTA (DTA-FL) (hatched bar) or FL without DTA (Vehicle-
FL) (dotted bar) for 30 min at 37‡C. After culturing for 24 h, the viability of the cells was measured by Alamar blue assay as de-
scribed in Section 2. Data represent the mean+S.D. for triplicate experiments. (B) Flow cytometric analysis of surface makers on sepa-
rated cells. Cells were stained with anti-human CD14 antibody, anti-human CD19 antibody or anti-human CD3 antibody, then sub-
jected to £ow cytometry.
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the other hand, DTA-FL caused a partial decrease in
viability of T-cells. Vehicle-FL did not a¡ect the vi-
ability of any kind of cell. The populations of the
separated cells were con¢rmed by £ow cytometry
(Fig. 2B). These results indicate that FL can fuse
with and deliver DTA into monocytes, whereas FL
cannot fuse with B-cells. Since T-cells seem to in-
clude subpopulations with which FL cannot fuse,
we then separated T-cells into CD4, CD8, and
CD43/CD83 cells using anti-CD4 and CD8 anti-
body-conjugated microbeads and examined the reac-
tivity of each with FL. As shown in Fig. 3, we found
that DTA-FL did not reduce the viability of CD4
T-cells or CD8 T-cells; however, it killed CD43/
CD83 T-cells. These results indicate that FL can
fuse with and deliver DTA into CD43/CD83 T-cells,
but can do neither with CD4 T-cells or CD8
T-cells.
3.3. Fusion between FL and human leukemia cells
Next, we examined the reactivity of DTA-FL with
cultured human blood cells. Six types of typical cul-
tured human leukemia cell lines were selected: U937
(monoblastic leukemia), Daudi and BALL1 (B-lym-
phoma), MOLT4 and Jurkat (T-lymphoma), and
K562 (erythroblastic leukemia). DTA-FL was incu-
bated with these cells and then cell viability was
measured. As shown in Fig. 4, DTA-FL caused the
most marked decrease in viability of U937 cells,
whereas it did not a¡ect K562 cells. The sensitivity
to DTA-FL, in decreasing order, was as follows:
U937 (monoblastic leukemia)sMOLT4, Jurkat (T-
lymphoma)sDaudi, BALL1 (B-lymphoma)sK562
(erythroblastic leukemia). These results correlate well
with the demonstrated susceptibility of PBMC
against FL; i.e. both in PBMC and cultured blood
Fig. 3. Cell type speci¢c fusion of FL among T-cells. Human T-cells were separated from PBMC and T-cell subpopulations were ob-
tained as described in Section 2. Susceptibility to DTA-FL was examined (A) and the expression of cell surface markers was con-
¢rmed by £ow cytometry (B). (A) Susceptibility to FL. Cells were incubated with FL containing DTA (DTA-FL) (hatched bar) for
30 min at 37‡C. After culturing for 24 h, the viability of the cells was measured by Alamar blue assay as described in Section 2. Data
represent the mean+S.D. for triplicate experiments. *For CD43/CD83 T-cells, the change in OD due to the co-existence of platelets
in the well was subtracted. (B) Flow cytometric analysis of surface makers on separated cells. Cells were stained with anti-human
CD4 antibody and anti-human CD8 antibody.
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cell lines, FL showed same reactivity with cells be-
longing to the same population. For example, FL
had high reactivity with both peripheral blood
monocytes and monoblastic leukemia U937 cells,
whereas FL had very little reactivity with both pe-
ripheral blood B-cells and cultured B-lymphoma cell
lines such as Daudi and BALL cells (Figs. 2 and 4).
3.4. Binding between FL and human leukemia cells
Because binding of viral envelope proteins with
target cells is thought to be a critical step in the
fusion between the Sendai virus and cells [13], we
next tried to determine whether FL can bind with
cells which cannot fuse with FL (FL-resistant cells).
The binding ability of FL to both permissive and
non-permissive human leukemia cells was examined
using calcein-containing FL (calcein-FL). The cells
were incubated with calcein-FL and the £uorescence
intensity of cells was measured by £ow cytometry
(Fig. 5). In all cell lines examined, the £uorescence
intensity of the cells increased by an almost equal
degree after incubation with calcein-FL. On the other
hand, incubation with calcein-liposomes not contain-
ing Sendai virus-derived proteins did not increase the
£uorescence intensity of the cells, indicating that
these liposomes do not bind with the cells. The
data indicate that FL can bind with all these cell
lines depending on the presence of Sendai virus-de-
rived proteins. These results suggest that FL can
bind with the cells, but binding is not su⁄cient to
membrane fusion.
4. Discussion
We have revealed the target-cell speci¢city of
membrane fusion-mediated macromolecule delivery
by FL into human blood cells. The use of DTA as
a model encapsulated molecule in FL provided good
evidence of a direct fusion between FL and the cy-
toplasmic membrane, based on the following. DTA
is known to inactivate elongation factor 2 and to
stop protein synthesis in the cytosol of target cells.
One molecule of DTA can kill a cell, if it is intro-
duced into the cell through membrane fusion and
not through endocytosis [6,14]. In addition, com-
pared to the reporter gene assay, which is often
used to examine the target-cell speci¢city of gene
transfer vectors, this system has an advantage in
that the evaluation of target-cell speci¢city is in no
way a¡ected by the gene expression activity of the
cells. Using this excellent marker, we were here able
to examine the target-cell speci¢city of FL in human
blood cells and to discover the existence of FL-resist-
ant cells.
From the standpoint of investigating the mecha-
nisms of membrane fusion, the existence of FL-re-
sistant cells (even though they can bind with FL) is
interesting. Since fusion between FL and cell depends
on the envelope proteins derived from the Sendai
virus [7], these proteins may work similarly on FL
and the Sendai virus. As to the membrane fusion
between the Sendai virus and cells, two types of en-
velope proteins, F and HN protein, are known to be
Fig. 4. Susceptibility of human leukemia cell lines to DTA-FL.
Cells were incubated with DTA-FL for 30 min at 37‡C. After
culturing for 24 h, viability of the cells was measured by Ala-
mar blue assay as described in Section 2. Data represent the
mean þ S.D. for triplicate experiments. Closed circle, K562 (er-
ythroblastic leukemia); closed square, Daudi (B-lymphoma);
open square, BALL1 (B-lymphoma); closed triangle, MOLT4
(T-lymphoma); open triangle, Jurkat (T-lymphoma); open
circle, U937 (monoblastic leukemia). The mean þ S.D. value of
OD5703OD595 by reduction of Alamar blue dye for each un-
treated cell was as follows: 0.880 þ 0.007 for K562,
0.677 þ 0.019 for Daudi, 0.790 þ 0.014 for BALL-1,
0.818 þ 0.019 for Jurkat, 0.812 þ 0.007 for MOLT4 and
0.819 þ 0.014 for U937. These values suggested that the varia-
tion of proliferative activity among these cells is small.
BBAMEM 77541 4-1-99
A. Watabe et al. / Biochimica et Biophysica Acta 1416 (1999) 339^348 345
necessary. When the Sendai virus fuses with a cell,
viral HN protein binds to the cell surface, and F
protein then causes membrane fusion [21^24]. Sialic
acid on the cell membrane is known to function as a
binding target for HN protein [21,25], and the exist-
ence of a binding target for HN protein is believed
to determine the susceptibility of fusion. In the
present study, FL could bind to, but could not fuse
with, FL-resistant cells. This means that binding to
the cell surface is insu⁄cient for FL to fuse with the
cell membrane. In Fig. 5, binding of FL to Jurkat
and MOLT4 cells was lower than to other cells in-
cluding U937 cells. As shown in Fig. 4, DTA-FL
showed higher reactivity with U937 cells than Jurkat
and MOLT4 cells. If we consider only the results
about U937, Jurkat, and MOLT4 cells, a possibility
that the slight di¡erence in binding leads to a more
pronounced preferential cell killing by DTA-FL can-
not be completely denied. However, FL showed the
binding activity with all cell lines examined, depend-
ing on the existence of envelope proteins, despite
these cells showed the large variation of the reactivity
with DTA-FL. Therefore we concluded that the
binding is not a critical step which determines the
reactivity of FL with cells.
There are two possible explanations for this phe-
nomenon. One is that not only sialic acid, but also
other cell-surface molecules may be involved in the
fusion between FL and cells, and FL-resistant cells
may lack these molecules. Based on the report that
HN protein has an unknown, but important, role in
membrane fusion as well as receptor binding
[22,23,26], it is speculated that HN protein may par-
ticipate in membrane fusion by interacting with un-
known molecules on the cell. The second possibility
is that FL-resistant cells may possess an inhibitory
factor for membrane fusion.
Research into these factors may provide important
information not only for elucidating the mechanisms
of membrane fusion, but also for improvement of the
delivery by FL. In cases in which FL would be ap-
plied as a carrier to transfer biological materials into
B-cells, CD4 T-cells, or CD8 T-cells, FL would
have to be modi¢ed in order to fuse with these cells.
Fig. 5. Binding of calcein-containing FL with human leukemia cells. Cells were incubated with calcein-containing FL (OD540 = 0.1)
(middle panels) or Sendai virus-free liposomes containing calcein (bottom panels) at 37‡C for 30 min. After washing with PBS(3), the
£uorescence intensity of the cells was measured by £ow cytometry. The £uorescence intensity of untreated cells was measured as a
negative control (top panels). The values of y-axes show relative cell number.
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Information on the mechanisms of membrane fusion
between FL and cells would be helpful in this regard.
In regard to FL as a therapeutic tool, the target-
cell speci¢city we revealed here may be applicable for
various purposes. For example, FL may be used for
the treatment of genetic or infectious diseases in
which monocytes are therapeutic targets, such as
chronic granulomatous disease [27], Gaucher’s dis-
ease [28] or AIDS [29]. We found that some T-lym-
phoma cell lines were also preferred targets of FL,
although the majority of primary cultured T-lympho-
cytes were almost resistant. This characteristic
prompts us to think that cancer cells derived from
T-lymphocytes might obtain the reactivity with FL
after their transformation. If FL can fuse with pe-
ripheral blood leukemia cells, it might be used to
deliver anti-cancer materials speci¢cally to tumor
cells. In this way, FL might be useful in the treat-
ment of leukemia. The reactivity of FL with periph-
eral blood leukemia cells will be an important subject
for future research. Our ¢ndings make an important
contribution to the basic characterization of FL.
Further study of the mechanism of membrane fusion
using FL-resistant cells will make it possible to mod-
ulate the target speci¢city of FL.
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